文献速递其他结缔组织病

基于母体疾病、治疗及抗Ro/La抗体水平预测胎儿房室传导

Prediction of foetal atrioventricular conduction using maternal disease, treatment and anti-Ro/La autoantibody levels.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该研究纳入324例抗Ro/La抗体阳性妊娠,分析母体疾病、抗风湿治疗及抗体水平与胎儿房室传导的关系。发现原发性干燥综合征(SjD)与胎儿房室时间延长相关,硫唑嘌呤(AZA)与缩短相关,抗La抗体高水平与房室传导阻滞(AVB)风险增加相关,但常规抗体检测预测AVB性能较低。

要点

  • 原发性干燥综合征孕妇胎儿房室时间较无SjD/SLE者延长(130.5 vs 125.8 ms,P=0.002)。
  • AZA暴露与胎儿房室时间缩短相关(122.5 vs 128.7 ms,P=0.038)。

核心结论

  • 母体原发性干燥综合征与胎儿房室时间延长相关,AZA治疗与缩短相关,抗La抗体高水平与AVB风险增加相关,但常规抗体检测预测AVB性能低。

研究设计与样本

  • 纳入324例抗Ro/La抗体阳性妊娠,其中监测组302例(含9例AVB),心动过缓组22例(新诊断AVB II-III)。
  • 分析胎儿房室传导及常规抗Ro52、抗Ro60、抗La抗体水平。

主要发现

  • 原发性干燥综合征孕妇胎儿房室时间较无SjD/SLE的抗体阳性孕妇延长(130.5±11.9 vs 125.8±8.7 ms,P=0.002)。
  • AZA治疗者胎儿房室时间较未治疗者缩短(122.5±8.9 vs 128.7±11.0 ms,P=0.038)。
  • 常规抗体检测可将近20%妊娠识别为低风险,但三种抗体对AVB II-III的阳性预测值在100%灵敏度下不足5%。

关键数值与推荐

  • 常规抗Ro52、抗Ro60、抗La抗体检测可识别近20%妊娠为低风险。
  • 三种抗体对AVB II-III的阳性预测值在100%灵敏度下未达5%。

临床怎么用

  • 对原发性干燥综合征合并抗Ro/La抗体阳性孕妇应加强胎儿房室传导监测。
  • AZA治疗可能缩短胎儿房室时间,但需结合病情个体化评估。
  • 常规抗Ro/La抗体检测预测AVB性能有限,不宜单独用于风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the relationship between maternal disease, anti-rheumatic treatment, autoantibody levels and foetal atrioventricular (AV) conduction. METHODS: A total of 324 pregnancies from two groups of anti-Ro/La autoantibody-positive women were included. The Surveillance group consisted of pregnancies with known anti-Ro positivity followed from early pregnancy; n = 302, including nine with AV block (AVB), and the Bradycardia group with no prior knowledge of anti-Ro/La autoantibodies and referred upon detection of foetal bradycardia, with a subsequent AVB II-III diagnosis (n = 22). Foetal AV conduction and routine anti-Ro52, anti-Ro60 and anti-La autoantibody levels were analysed. RESULTS: Women with primary Sjögren disease (SjD) had longer foetal AV time intervals (130.5 ± 11.9 vs 125.8 ± 8.7 ms, P = 0.002) compared with autoantibody-positive women with neither SjD nor SLE. Notably, AZA, mostly used in women with SLE, was associated with shorter foetal AV time intervals compared with autoantibody-positive pregnancies without AZA treatment (122.5 ± 8.9 vs 128.7 ± 11.0 ms, P = 0.038). For antibody-based prediction, anti-Ro52, anti-Ro60 and anti-La antibody levels obtained from routine assays could identify nearly 20% of pregnancies as low risk, and high levels (≥8 U/ml) of anti-La antibodies were associated with an increased risk of AVB I-III (OR = 6.0, 1.26-28.5). However, the positive predictive value for AVB II-III of the three autoantibodies did not reach 5% for a sensitivity of 100%. CONCLUSION: This report, based on over 20 years of surveillance of anti-Ro positive pregnancies, identifies associations between maternal disease, their treatments and foetal AV conduction. Routine detection assays for anti-Ro/La antibodies had low performance in predicting AVB among an anti-Ro/La positive population.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Martin de Frémont G, Rudolph L, da Silva Rodrigues R, et al. Prediction of foetal atrioventricular conduction using maternal disease, treatment and anti-Ro/La autoantibody levels. Rheumatology (Oxford). 2026. PMID: 41564310. doi:10.1093/rheumatology/keag022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。